Definitive Contract 75N91018C00024
Award Date
9/17/18
Potential Completion Date
6/17/19
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Cellsight Technologies, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Francisco, CA 94107, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $247,568 Firm Fixed Price contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for research and development related to a novel PET imaging agent, [18F]F-ARAG, to assess response to cancer immunotherapies. This contract is part of NCI's Small Business Innovation Research (SBIR) program, which sets aside certain research and development contracts for small businesses. Cellsight Technologies has also...
This is a $300,000 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business, under the Small Business Innovation Research (SBIR) program. The purpose of the contract is to evaluate [18F]F-ARAG, a T cell-specific Positron Emission Tomography (PET) imaging agent, as a biomarker to predict response to cancer immunotherapies. This Phase I SBIR contract builds on a previous $2 million...
This is a $1,995,174 Firm Fixed Price (FFP) Definitive Contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for SBIR Phase II research and development of the [18F]F-ARAG imaging agent to assess response to cancer immunotherapies in non-small cell lung cancer. This builds on a previous $300,000 SBIR Phase I contract from NCI to evaluate [18F]F-ARAG for predicting response to cancer immunotherapies. The contract...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
<p>This is a $249,330.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to ITI Health, Inc. (doing business as Zielbio) for a Small Business Innovation Research (SBIR) Phase I project on novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract was awarded on September 30, 2011 with a completion date of December 5, 2013. This award is designated as a Total Small Business set-aside contract.</p>
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This definitive firm fixed price contract from the Department of Health and Human Services National Institutes of Health National Cancer Institute, with a total small business set aside, is for $299,726.89 to Imago Systems Inc. for the development of a novel diagnostic imaging modality for monitoring tumor responses to a hyperthermia immunotherapy as part of the National Cancer Institute's Moonshot initiative. The award stems from Topic 375 of the NIH/CDC SBIR Contract Solicitation PHS 2018-1,...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
This is a $1,997,803 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc., a small business manufacturer of specialized biomedical research equipment and tools. The contract is for the topic "Integrated Imaging and Molecular Analysis of Glioblastoma Using SCOPE SEQ on the Air Flow" and has a total small business set-aside designation. The contract will support...